Business
New to The Street TV / Newsmax TV Announces its Five Corporate Interviews on Episode 484, Airing Saturday, July 01, 2023, 3:30 PM ET
New to The Street TV / Newsmax TV Announces its Five Corporate Interviews on Episode 484, Airing Saturday, July 01, 2023, 3:30 PM ET.
About this update from Sustainable Green Team, Ltd.
[{"type":"text","content":"\n NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax announces its 484th show line-up, which features five (5) Corporate interviews, airing Saturday, July 01, 2023, 3:30-4:00 PM ET. 1). Biopharmaceutical – Acurx Pharmaceuticals, Inc.'s (NASDAQ: ACXP) ($ACXP) interview with David Luci, President/CEO. 2). Sustainable Solutions – The Sustainable Green Team, Ltd.'s (OTCQX: SGTM) ($SGTM) \"Green Revolution\" episode on its subsidiary, Mulch Manufacturing, Inc. 3). Water Company – OriginClear, Inc.'s (OTC: OCLN) ($OCLN) interview with Ken Berenger, Executive Vice-President. 4). Digital Wellness – Hapbee Technologies, Inc.'s  (OTCQB: HAPBF) (TSXV: HAPB) (FSE: HA1) ($HAPBF) interview with Yona Shtern, CEO/Founder. 5). \"Sekur Privacy & Sekur Security Segment -The Weekly Hack\" interview with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQX: SWISF) (CSE: SKUR) (FRA: GDT0) ($SWISF) (Sekur®). Episode 484 David Luci, the President/CEO at Acurx Phamaceuticals, Inc. (NASDAQ: ACXP) ($ACXP), is at the Nasdaq Marketsite studio, talking with New to The Street's TV Host Jane King about the Company. Acurx Phamaceuticals, Inc. is a clinical-stage biopharmaceutical business developing a new class of antibiotics for life-threatening bacterial infections. David provides viewers with an update on the Company's FDA Phase 2b trial on its Ibezapolstat drug for treating Clostridioides difficile Infections (CDI) (C. diff). Enrolled in the trial are thirty-six patients, and Management expects that patient enrollment will end in December 2023. The current FDA trial is one of three value propositions the Company pursues throughout the second half of 2023. With bi-partisan support, the US Congress looks to pass the PASTEUR Act of 2023, designed to allow federal funds to flow to companies like Acurx that are developing a new class of antibiotic treatments for highly infectious diseases. The $370.5M congressional earmark will help create new antibiotics to save lives and reduce healthcare costs by approximately $2B over the next 10 years. Medicaid, Medicare, and VA patients will receive these new antibiotics at no cost. Current treatments for Clostridioides difficile Infections (CDI) (C. diff) and MRSA (methicillin-resistant Staphylococcus aureus) have become resis...